synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-31. Anything still debated is marked as such rather than presented as settled.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Conventional procedure === To measure the hydration band, a small slice of material is typically cut from an artifact. This sample is ground down to about 30 micrometers thick and mounted on a petrographic slide (this is called a thin section). The hydration rind is then measured under a high-power microscope outfitted with some method for measuring distance, typically in tenths of micrometers. The technician measures the microscopic amount of water absorbed on freshly broken surfaces. The principle behind obsidian hydration dating is simple–the longer the artifact surface has been exposed, the thicker the hydration band will be.
==== Absorption ==== Carvedilol is about 25% to 35% bioavailable following oral administration due to extensive first-pass metabolism. Absorption is slowed when administered with food, however, it does not show a significant difference in bioavailability. Taking carvedilol with food decreases the risk of orthostatic hypotension.
=== Tree === Aristotelia chilensis is a small dioecious evergreen tree that can reach 4 to 5 metres (13 to 16 ft) in height. Its divided trunk has a smooth bark. Its branches are abundant, thin and flexible. Its leaves are simple, opposite, hanging, oval-lanceolate, naked and coriaceous, with serrated edges. The leaf venation is highly visible, and the leaf stalk is a strong red color. In the beginning of spring, the tree sheds the old leaf cohort, which is used as a carbohydrate source to form the new leaves and flowers.
where the carbon-12 nucleus used in the first reaction is regenerated in the last reaction. After the two positrons (emitted by beta-plus decay) annihilate with two ambient electrons producing an additional 2.04 MeV, the total energy released in one cycle is 26.73 MeV; in some texts, authors are erroneously including the positron annihilation energy in with the Q-value for beta-decay and then neglecting the equal amount of energy released by annihilation, leading to possible confusion. All values are calculated with reference to the Atomic Mass Evaluation 2003. The limiting (slowest) reaction in the CNO-I cycle is the proton capture on 147N. In 2006 it was experimentally measured down to stellar energies, revising the calculated age of globular clusters by around 1 billion years. The neutrinos emitted in beta decay will have a spectrum of energy ranges, because although momentum is conserved, the momentum can be shared in any way between the positron and neutrino, with either emitted at rest and the other taking away the full energy, or anything in between, so long as all the energy from the Q-value is used. The total momentum received by the positron and the neutrino is not great enough to cause a significant recoil of the much heavier daughter nucleus and hence, its contribution to kinetic energy of the products, for the precision of values given here, can be neglected. Thus the neutrino emitted during the decay of nitrogen-13 can have an energy from zero up to 1.20 MeV, and the neutrino emitted during the decay of oxygen-15 can have an energy from zero up to 1.73 MeV.
Sources: en.wikipedia.org
== Prevalence == A number of studies have examined the prevalence of link rot within the World Wide Web, in academic literature that uses URLs to cite web content, and within digital libraries. In a 2023 study of the Million Dollar Homepage external links, it was found that 27% of the links resulted in a site loading with no redirects, 45% of links have been redirected, and 28% returned various error messages. A 2002 study suggested that link rot within digital libraries is considerably slower than on the web. The article found that about 3% of the objects were no longer accessible after one year, equating to a half-life of nearly 23 years. A 2003 study found that on the Web, about one link out of every 200 broke each week, suggesting a half-life of 138 weeks. This rate was largely confirmed by a 2016–2017 study of links in Yahoo! Directory (which had stopped updating in 2014 after 21 years of development) that found the half-life of the directory's links to be two years. A 2004 study showed that subsets of Web links (such as those targeting specific file types or those hosted by academic institutions) could have dramatically different half-lives. The URLs selected for publication appear to have greater longevity than the average URL. A 2015 study by Weblock analyzed more than 180,000 links from references in the full-text corpora of three major open access publishers and found a half-life of about 14 years, generally confirming a 2005 study that found that half of the URLs cited in D-Lib Magazine articles were active 10 years after publication.
== Genetics == The gene for G-CSF is located on chromosome 17, locus q11.2-q12. Nagata et al. found that the GCSF gene has four introns, and that two different polypeptides are synthesized from the same gene by differential splicing of mRNA. The two polypeptides differ by the presence or absence of three amino acids. Expression studies indicate that both have authentic GCSF activity. It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element.
The largest concentration of Southern Rhodesian troops in the Italian Campaign of 1943–45 was the group of about 1,400, mainly from the Southern Rhodesian Reconnaissance Regiment, spread across the South African 6th Armoured Division. The 11th South African Armoured Brigade, one of the 6th Division's two main components, was made up of Prince Alfred's Guard, the Pretoria Regiment (Princess Alice's Own) and the Special Service Battalion, each of which had a Rhodesian squadron of Sherman tanks. The other, the 12th South African Motorised Brigade, comprised infantry—the Witwatersrand Rifles, the Natal Carbineers and the Cape Town Highlanders, the last of which had a large Rhodesian contingent. There were also two Rhodesian artillery batteries—the original Rhodesian Anti-Tank Battery and a newer unit of Rhodesian field gunners. After a year's training in Egypt, the division sailed to Italy in April 1944, landing towards the end of the month at Taranto. No. 237 Squadron, now flying Spitfires, rebased to Corsica the same month to operate over Italy and southern France. The 6th Division moved north-west from Taranto to take its place as part of the Eighth Army alongside the US Fifth Army. It took part in the fourth and final Allied assault of the Battle of Monte Cassino in the second and third weeks of May 1944, helping to force the Germans out, and thereafter advanced north-west up the Liri valley to join the Allied forces at Anzio and advance onwards to Rome.
An unsaturated fat is a fat (triglyceride) containing at least one alkene group. Unsaturated fats can be further classified: monounsaturated fats, polyunsaturated fats, cis and trans fats. They are colorless. Unsaturated fats are derived from unsaturated fatty acids, common examples of which are oleic acid and linoleic acid. In cellular metabolism, unsaturated fat molecules contain slightly less energy (i.e., fewer calories) than an equivalent amount of saturated fat. The greater the degree of unsaturation in a fatty acid (i.e., the more double bonds in the fatty acid) the more susceptible it becomes to lipid peroxidation (rancidity).
== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.